5. Cinqair


Active ingredient: reslizumab
Disease: severe eosinophilic asthma
Peak sales estimate: $300 million
Approved: March 23
Company: Teva

The scoop: It wasn’t all that long ago that there were no drugs specifically approved to treat severe eosinophilic asthma. But by the time Teva’s Cinqair came around, GlaxoSmithKline’s Nucala was already on the scene, making it the med to beat. Unfortunately for Teva, GSK may have the edge when it comes to dosing convenience: Nucala is administered subcutaneously, while Cinqair is an intravenous formulation. But that’s not all Teva has to worry about. AstraZeneca pipeline therapy benralizumab—another subcutaneous product—has data in hand that may support less frequent dosing than both its on-market rivals. —Carly Helfand

5. Cinqair

Suggested Articles

Biotech leaders criticized the dismissals of Chinese scientists from U.S. universities in a letter with more than 150 signatures.

In this week's EuroBiotech Report, Merck allies with Themis on vaccine R&D, Juvenescence raises $100 million and GSK files for anemia approval. 

In our EuroBiotech roundup this week, Scancell withdraws IND, Oxurion’s eye drug fails phase 2a and Abivax starts ulcerative colitis trial.